Scope and Claims Analysis for US Patent 7,619,001 (Multiple Sclerosis Treatment Using Dimethyl Fumarate / Methyl Hydrogen Fumarate)
US 7,619,001 claims a method of treating multiple sclerosis using a pharmaceutical preparation containing dimethyl fumarate (DMF), methyl hydrogen fumarate (MHF), or combinations, with multiple claim layers tightening (i) dose ranges, (ii) dosage form, and (iii) microtablet and enteric-coating parameters.
What is actually claimed: method scope, not composition scope
All independent and dependent claims are framed as “A method of treating multiple sclerosis” by administering an amount of a pharmaceutical preparation effective for treating multiple sclerosis. This matters for landscape strategy because the patent is directed to medical use via administration, not to manufacturing or to the preparation in the abstract.
Core claim elements shared by all claims
- Target indication: multiple sclerosis
- Act of infringement: administering to a patient in need of treatment
- Drug substance: DMF, MHF, or combinations
- Formulation elements: at least one excipient and/or carrier
The method format creates practical enforcement pathways:
- Any product that makes up a patient regimen with the claimed DMF/MHF formulation could fall into scope if claim elements are met.
- Generic ANDA filing activity is less directly relevant than clinical regimen and label-level administration, because this is a method claim that is typically evaluated against product use rather than isolated formulation possession.
What is the independent claim (Claim 1) covering?
Claim 1 (independent): broadest asserted perimeter
Claim 1 covers:
- Method of treating multiple sclerosis
- Administering an effective amount of a pharmaceutical preparation
- The preparation includes at least one of:
- at least one excipient, and/or
- at least one carrier, and/or
- combinations of excipient and carrier
- The preparation contains:
- dimethyl fumarate, methyl hydrogen fumarate, or a combination
Practical implications of Claim 1 breadth
Claim 1 is broad because it does not, by itself, require:
- a specific DMF/MHF dose range (that appears in dependent claims),
- a specific dosage form (capsule/microtablet appear in dependents),
- an enteric coating feature (appears in later dependents),
- a microtablet size parameter.
So Claim 1 captures essentially any DMF/MHF-based MS regimen using a preparation with conventional excipients and/or carriers, provided the preparation is administered for the claimed indication.
How do the dependent claims narrow the scope (dose, dosage form, microtablet specs)?
The claim set uses tiered fall-through limitations that can be mapped to product design choices.
Dose limits and DMF amount thresholds
Claims 2 and 7 to 12 provide explicit quantitative boundaries.
Claim 2: DMF/MHF amount range
- DMF, MHF, or combination is present in 10 to 300 mg in the pharmaceutical preparation.
This is a formulation-level dose ceiling and floor that can exclude very low-dose or very high-dose presentations, depending on how “pharmaceutical preparation” is defined for the product unit.
Claims 7-12: minimum DMF amounts with discrete variants
For DMF-containing preparations (Claim 6 lineage), the claims define specific DMF amounts:
- Claim 7: at least 50 mg DMF
- Claim 8: at least 110 mg DMF
- Claim 9: at least 120 mg DMF
- Claim 10: 50 mg DMF
- Claim 11: 110 mg DMF
- Claim 12: 120 mg DMF
Capsules as a dosage container
- Claim 3: DMF/MHF preparation provided in one or more capsules
- Claims 16-18 add per-capsule DMF minimums:
- Claim 16: at least 50 mg DMF in each capsule
- Claim 17: at least 110 mg DMF
- Claim 18: at least 120 mg DMF
This creates a “product packaging” constraint: tablets vs capsules could avoid or reduce claim alignment unless other dependent routes apply.
Formulation type: oral and solid dosage
- Claim 13: formulated for oral administration
- Claim 14: formulated as a solid dosage form
Microtablets (and optional enteric coating)
The microtablet pathway is one of the key design-specific legs.
- Claim 15: solid dosage is microtablets
- Claim 19: microtablets are enteric-coated
And Claim 20-21 define a microtablet size parameter:
- Claim 20: mean diameter range 0.3 mm to 2.0 mm, exclusive of any coating
- Claim 21: mean diameter 2.0 mm, exclusive of any coating
This can be used as a hard differentiation line for a generic or alternate formulation: even if DMF/microtablets exist, the microtablet size distribution and coating exclusion logic can matter.
What combinations are explicitly covered?
- Claim 1 covers DMF, MHF, or combination.
- Claim 4 explicitly requires a combination of DMF and MHF.
- Claim 5 explicitly requires methyl hydrogen fumarate.
- Claim 6 explicitly requires dimethyl fumarate.
This means the landscape has at least three “design lanes”:
- DMF-only formulations
- MHF-only formulations
- DMF + MHF combinations
Claim chart style mapping: what each layer adds
| Claim |
New limitation added |
Scope impact |
| 1 |
MS method; administer effective amount; excipient/carrier; DMF/MHF present |
Broadest method perimeter |
| 2 |
DMF/MHF amount is 10-300 mg |
Narrows by dose window |
| 3 |
Administered as capsules |
Narrows by dosage form |
| 4 |
includes DMF + MHF combination |
Narrows by actives composition |
| 5 |
includes MHF |
Narrows by actives composition |
| 6 |
includes DMF |
Narrows by actives composition |
| 7-9 |
DMF in preparation: ≥50 / ≥110 / ≥120 mg |
Narrows by specific dose thresholds |
| 10-12 |
DMF in preparation: 50 / 110 / 120 mg |
Narrows further to specific unit amounts |
| 13 |
formulation for oral administration |
Adds route |
| 14 |
solid dosage form |
Adds physical form |
| 15 |
microtablets |
Adds dosage architecture |
| 16-18 |
DMF per capsule: ≥50 / ≥110 / ≥120 mg |
Adds unit-by-unit dosing |
| 19 |
enteric-coated microtablets |
Adds dissolution protection |
| 20-21 |
microtablet mean diameter 0.3-2.0 mm or 2.0 mm (no coating) |
Adds measurable geometry |
How Claim 1 interacts with the rest: “barbell” risk across product design
The structure creates two enforcement-relevant corridors:
1) Broad corridor via Claim 1
If a company markets a DMF/MHF MS regimen using a preparation with excipients/carriers and administered orally as a treatment, Claim 1 can read broadly, even if the product does not match capsule or microtablet details.
2) Hard corridor via microtablet-enteric-size dependents
If a product uses microtablets, enteric coating, and falls into the microtablet diameter band, dependent claims can become highly specific and easier to evaluate on product specs.
Patent Landscape: What this claim set implies for US competitors and generics
Why this patent is likely to be a “format-sensitive” competitive constraint
Even without invoking other patents, the claim set’s narrowing features target:
- oral solid microtablet architectures,
- enteric-coated functionality,
- microtablet diameter windows.
That makes Claim 1 plus the microtablet dependents a template for evaluating whether alternative formulations (different coatings, different unit sizes, different actives ratio handling) remain within risk.
Claim “design-around” levers within the text
A competitor seeking to reduce literal alignment could look to avoid one or more claim elements. The text itself creates levers:
- Active handling
- Use a formulation that does not include DMF or MHF in the claimed manner (e.g., different fumarate derivatives not listed).
- Dose per unit
- Avoid placing DMF/MHF within 10-300 mg “in the pharmaceutical preparation.”
- Dosage form
- Avoid capsules if the product is in tablets/sachets and the system is not “one or more capsules.”
- Microtablet architecture
- Avoid microtablets; use another solid form that is not “microtablets.”
- Enteric coating
- Avoid enteric-coated microtablets if the formulation does not coat in the claimed way.
- Microtablet diameter
- Avoid the mean diameter constraints 0.3 mm to 2.0 mm and 2.0 mm (exclusive of coating).
These levers matter because US 7,619,001 is method-based but still anchored to product composition and measurable formulation properties.
Scope for DMF-only vs DMF/MHF combination products
The claim set separately supports DMF-only and DMF + MHF combination presentations. A product using only DMF (without MHF) still aligns through:
- Claim 1 (DMF present),
- Claim 6 and dependent DMF dose thresholds (Claims 7-12, and capsule dose thresholds 16-18).
A DMF/MHF combination product aligns through:
- Claim 1 (combination),
- Claim 4 (combination),
- and could also align through the DMF threshold dependents depending on actual DMF amount.
Enforceability emphasis: measurable specs are claim-critical
The microtablet dependents use measurable parameters:
- “mean diameter” with explicit numeric bounds
- “exclusive of any coating” (i.e., coating thickness is excluded from diameter measurement logic)
This is the most objective region of the claim set, and it becomes the hinge for product comparison in due diligence, whether for Freedom-to-Operate or validity/impact mapping.
Key Takeaways
- US 7,619,001 claims an MS treatment method that requires administering a pharmaceutical preparation containing DMF and/or MHF plus conventional excipient/carrier components.
- Claim 1 is broad: it does not require a specific DMF/MHF dose, capsule form, or microtablet/enteric-coated constraints.
- Dependent claims narrow sharply with:
- DMF/MHF amount 10-300 mg (Claim 2),
- DMF unit thresholds including 50 / 110 / 120 mg (Claims 7-12),
- dosage presentation in capsules (Claims 3, 16-18),
- microtablet architecture (Claim 15),
- enteric-coated microtablets (Claim 19),
- microtablet mean diameter 0.3-2.0 mm (Claim 20) and 2.0 mm (Claim 21), excluding coating.
- Competitive and generic risk assessment should prioritize whether the marketed regimen uses DMF/MHF, and if it uses microtablets with enteric coating and the specified diameter bands, because those features convert broad chemistry into tight, measurable claim alignment.
FAQs
1) Is this patent limited to DMF-only products?
No. It covers DMF, MHF, or combinations, with separate dependent claims for DMF-only (Claim 6), MHF-only (Claim 5), and DMF+MHF (Claim 4).
2) Does Claim 1 require a capsule formulation?
No. Claim 1 requires administering an effective MS-treatment preparation with excipient/carrier and DMF/MHF, but capsules are only required in Claim 3 and capsule-specific dependents.
3) What numeric dose constraints appear in the claims?
Claim 2 sets 10-300 mg for DMF/MHF in the pharmaceutical preparation. Claim 7-12 and 16-18 specify DMF thresholds as 50, 110, and 120 mg.
4) What formulation attributes are most diagnostic for infringement analysis?
The microtablet dependents are most diagnostic: microtablet identity, enteric coating, and mean microtablet diameter with numeric bounds excluding coating.
5) Is the patent framed as a composition patent or a method-of-use patent?
It is framed as a method of treating multiple sclerosis by administering a defined DMF/MHF-containing preparation.
References (APA)
[1] United States Patent No. 7,619,001.
